Welcome to our dedicated page for Davita SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DaVita Inc. (NYSE: DVA) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its kidney care operations, capital structure and governance. This page aggregates those SEC filings and pairs them with AI-powered tools to help readers understand the implications for the company’s dialysis and integrated kidney care business.
For DaVita, current reports on Form 8-K are particularly informative. Recent 8-K filings describe quarterly financial results, including consolidated revenues, operating income, cash flow and key U.S. dialysis metrics, as well as board actions such as increases to the company’s share repurchase authorization. Other 8-Ks outline material definitive agreements, including amendments to DaVita’s senior secured credit facilities that establish new term loan and revolving credit arrangements and explain how proceeds may be used for refinancing, working capital and general corporate purposes.
Investors following DVA can also use SEC filings to track topics such as share repurchases, debt issuance and integrated kidney care strategy. Disclosures around authorization levels for repurchase programs, limitations under credit agreements and the company’s approach to capital allocation appear in these documents. Filings related to financial results provide context on DaVita’s role as a comprehensive kidney care provider, its global network of outpatient dialysis centers and its participation in value-based care models.
On this page, AI-generated summaries highlight the main points of each filing, explain technical language and draw attention to items that may matter to shareholders, such as changes in credit facilities, repurchase authorizations or reported operating performance. Users can quickly locate DaVita’s quarterly and annual reports when available, review Form 8-K disclosures and examine any insider-related filings, while relying on AI assistance to interpret how these regulatory documents relate to the company’s kidney care operations and financial profile.
A DaVita Inc. (DVA) director reported acquiring 411 shares of common stock on 11/15/2025 at a stated price of $0, indicating this was likely a stock grant rather than an open-market purchase. Following this transaction, the director beneficially owns 2,089 DaVita shares, held in direct ownership. This is a routine insider ownership update showing a modest increase in the director’s equity stake.
DaVita Inc. director reports stock acquisition
A director of DaVita Inc. (DVA) reported acquiring 411 shares of DaVita common stock on 11/15/2025 in a transaction priced at $0 per share7,231 shares of DaVita common stock in direct ownership. This is a routine insider ownership update, disclosing the director’s latest equity position in the company.
DaVita Inc. director reports small stock acquisition
A director of DaVita Inc. (DVA) reported acquiring 411 shares of DaVita common stock on 11/15/2025 in a Form 4 filing. The shares were acquired at a stated price of $0, which typically indicates an equity award rather than an open-market purchase. Following this transaction, the director now beneficially owns 6,023 shares of DaVita common stock, held directly.
DaVita Inc. (DVA)11/15/2025 at a reported price of $0. Following this transaction, he is shown as holding 411 shares directly and 13,028 shares indirectly through the Marc J. Desoer and Barbara J. Desoer 1998 Trust dated September 7, 1998. The filing is reported as being made by one reporting person.
DaVita Inc. (DVA) director reports stock acquisition
A director of DaVita Inc. filed a Form 4 reporting the acquisition of 411 shares of common stock on 11/15/2025. The transaction is coded as an acquisition at a stated price of $0, which typically indicates a grant or similar award rather than an open-market purchase. Following this transaction, the reporting person beneficially owns 26,363 shares of DaVita common stock, held in direct ownership. The filing is made by a single reporting person and notes the individual’s role as a Director of the company.
DaVita Inc. (DVA) disclosed a Form 4 showing its Chief Executive Officer, who is also a director, had 5,165 shares of common stock withheld on 11/15/2025. These shares were withheld to cover tax obligations arising from the vesting of 12,474 restricted stock units, representing 33.333% of the original grant made on November 15, 2024. After this tax-withholding transaction, the reporting person directly beneficially owns 888,915 shares of DaVita common stock.
The Vanguard Group filed Amendment No. 14 to Schedule 13G reporting a passive stake in DaVita Inc. (DVA) as of 09/30/2025. Vanguard reported 4,227,904 shares beneficially owned, representing 5.91% of DaVita’s common stock.
Vanguard reported 0 shares with sole voting power and 214,553 with shared voting power. It reported 3,919,715 shares with sole dispositive power and 308,189 with shared dispositive power. The filing was made as an investment adviser (IA) and includes a certification that the securities are held in the ordinary course of business and not to change or influence control.
DaVita Inc. (DVA) insider filing reports a sale of 401,514 shares of common stock on 10/27/2025 at a price of $135.3558 per share. Following the transaction, the reporting persons collectively beneficially owned 31,759,065 shares, held indirectly.
Footnotes state that 15,126,977 shares are owned by Government Employees Insurance Company (a Berkshire Hathaway subsidiary). An additional 16,632,088 shares are held by pension plans: BNSF Master Retirement Trust 6,100,000 and Berkshire Hathaway Inc. Consolidated Pension Plan 10,532,088. The filing is signed “/s/ Warren E. Buffett” on behalf of the reporting persons.
DaVita Inc. filed its Q3 2025 10‑Q, reporting higher revenue and continued buybacks. Total revenues were $3,420,227 thousand, up from $3,263,590 thousand a year ago. Operating income was $505,767 thousand. Net income attributable to DaVita Inc. was $150,332 thousand, with diluted EPS of $2.04.
For the first nine months, revenues reached $10,023,282 thousand and net cash provided by operating activities was $1,345,774 thousand. The company repurchased 3,274 thousand shares in Q3 for $465,141 thousand and 10,001 thousand shares year‑to‑date for $1,461,387 thousand. As of October 28, 2025, approximately 70.6 million shares were outstanding.
DaVita issued $1,000,000 of 6.75% senior notes due 2033 and refinanced into a Term Loan B‑2 of $1,873,254; long‑term debt stood at $10,183,863 thousand. The weighted average effective interest rate on all debt was 5.70% in Q3. The company acquired Fresenius Medical Care’s Brazil dialysis operations for $94,282 thousand, contributing to total 2025 acquisition consideration of $108,015 thousand.
DaVita Inc. furnished an 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The information is being furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth. Additional materials include Exhibit 104.0 for the cover page Inline XBRL tags.